Q2 Solutions Q2 Solutions Actionable Insights for Better Health and Lab Solutions
Refine Results

Genomic technologies have been widely adopted within oncology, according to Patrick Hurban, Ph.D., senior director and global head, Genomic Development/Esoteric Assays at Q2 Solutions. In the second video from a three-part series, Hurban discusses the use of genomics in oncology trials and many other therapeutic areas as well. Watch Part two Related Services: Anatomic Pathology Services Biomarker Services Central Laboratories Companion Diagnostics Genomic Laboratories Precision Medicine

In part one of a three-part video series, Patrick Hurban, Ph.D., senior director and global head, Genomic Development/Esoteric Assays at Q2 Solutions, discusses the significance of genomic technologies in clinical trials. Dr. Hurban shares his perspective on genomic technologies and the future of precision medicine as well as how both will impact healthcare globally. Watch Part one

Mark Edinger | December 17, 2015

Until recently most flow cytometers were routinely characterized and calibrated using beads that contained surrogate dyes, with standardized quantitative measurements restricted to those few fluorochromes for which Molecules of Equivalent Soluble Fluorochrome (MESF) beads or assay specific setup beads were available. What was needed were fluorochrome specific calibration beads that would allow all the detectors on any instrument to be setup to provide reproducible quantitative measurements of fluorescence on the same instrument day to day, across instruments, and across multiple instrument platforms.  To this end, working with BDTM, Q2 Solutions has developed a procedure for flow cytometry... Read More